Rivaroxaban found noninferior to enoxaparin in acutely ill

Rivaroxaban found noninferior to enoxaparin in acutely ill
In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, according to a study published in the Feb. 7 issue of the New England Journal of Medicine.

(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, according to a study published in the Feb. 7 issue of the New England Journal of Medicine.

Alexander T. Cohen, M.D., from King's College Hospital in London, and colleagues randomly assigned 8,101 patients (40 years of age and older) with reduced mobility and an acute requiring hospitalization to receive subcutaneous (40 mg once daily) for 10 days and oral placebo for 35 days, or subcutaneous placebo for 10 days and oral rivaroxaban (10 mg once daily) for 35 days.

At day 10, the researchers found that 2.7 percent of the rivaroxaban group and 2.7 percent of the enoxaparin group experienced asymptomatic proximal or symptomatic venous (relative risk, 0.97; P = 0.003 for non-inferiority). At day 35, 4.4 percent of the rivaroxaban group and 5.7 percent of the enoxaparin group experienced this outcome (relative risk, 0.77; P = 0.02). Major or clinically relevant non-major bleeding occurred in a significantly greater percentage of the rivaroxaban group both at day 10 (2.8 versus 1.2 percent) and at day 35 (4.1 versus 1.7 percent).

"The efficacy of standard-duration rivaroxaban was similar to that of enoxaparin, whereas the efficacy of extended-duration rivaroxaban was superior to that of enoxaparin," Cohen and colleagues conclude. "However, rivaroxaban was associated with an increased risk of clinically relevant bleeding."

The study was funded by Bayer, manufacturer of rivaroxaban, and Janssen, marketer of rivaroxaban; several authors disclosed to pharmaceutical companies, including Bayer and Janssen.

More information: Full Text (subscription or payment may be required)

Related Stories

Stroke risk high when anti-clotting drugs stopped

date Apr 25, 2012

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Recommended for you

Predicting chronic pain in whiplash injuries

date 37 minutes ago

While most people should expect to fully recover from whiplash injuries within the first few months, about 25 percent have long-term pain and disability that lasts many months or years.

What is campylobacter, and what are we doing about it?

date 5 hours ago

Campylobacters are spiral-shaped bacteria that often colonize the intestines of animals grown for food (as well as other animals)—and they can cause acute diarrheal disease (called campylobacteriosis) in ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.